Submitted:
14 October 2024
Posted:
14 October 2024
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Results
3. Discussion
3.1. Epidemiological, Statistical versus Clinical Model
3.1.1. Bias in Cohort Studies
3.1.2. Bias in High Specialisation Oncology
3.1.3. Thyroid Cancer Diagnosis, Rerporting, Estimation in Public Health
3.1.4. Translational Medicine
3.1.4. Misdiagnosis and False Survival
3.2. Clinical Model and Evidence-Based Medicine
3.3. Pathway and Time-Lapse Observation
3.3.1. Hormonal Signal and Homeostasis

3.3.2. Various Autoimmunity
3.3.3. Genetic Background and Immunity
4. Materials and Methods
4.1. Material
4.2. Methods Time-Lapse Data Collection
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Ethics approval and consent to participate
Informed Consent Statement
References
- Zdziarski P: Paściak M, Gamian A. Microbiome Analysis and Pharmacovigilance After Inhaled Glucocorticoid: Oral Dysbiosis With the Isolation of Three Rothia Species and Subsequent Sjögren's Syndrome. Front Pharmacol. 2022;13:636180. Published 2022 Apr 1. [CrossRef]
- Zdziarski P, Wzorek A. Respiratory microbiota as a good predictor of outcome in humoral immunodeficiency. Methodological and conceptual difficulties in comprehensive microbiome analysis. Pol Merkur Lekarski. 2022;50(299):287-293.
- Zdziarski P. Veillonella atypica in tumor as a tripartite interaction: commensal - tumor - patient. Pol Merkur Lekarski. 2020 Dec 22;48(288):452-456.
- C. Cappelli, M. Braga, E.D. Martino, M. Castellano, E. Gandossi, B. Agosti, et al. Outcome of Patients Surgically Treated for Various Forms of Hyperthyroidism with Differentiated Thyroid Cancer: Experience at an Endocrine Center in Italy Surg Today, 36 (2) (2006), pp. 125-130.
- Gopinath C, Crow H, Panthi S, Bantis L, Burman KD, Choudhary C. Characteristics, staging and outcomes of differentiated thyroid cancer in patients with and without Graves' disease. J Clin Transl Endocrinol. 2023 Jul 26;33:100321. [CrossRef]
- Elisei R., Viola D., Torregrossa L., Giannini R., Romei C., Ugolini C., Molinaro E., Agate L., Biagini A., Lupi C., Valerio L., Materazzi G., Miccoli P., Piaggi P., Pinchera A., Vitti P., Basolo F. The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97:4390–4398.
- Obołończyk Ł, Siekierska-Hellmann M, Wiśniewski P, Lewczuk A, Berendt-Obołończyk M, Lakomy A, Michalska Z, Radowska D, Moszkowska G, Bianek-Bodzak A, Sworczak K. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study. Postepy Hig Med Dosw (Online). 2017 Sep 25;71(0):842-849. [CrossRef]
- Nikiforova MN , Kimura ET , Gandhi M , Biddinger PW , Knauf JA , Basolo F , Zhu Z , Giannini R , Salvatore G , Fusco A , Santoro M , Fagin JA , Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88 : 5399 – 5404.
- Zdziarski P, Gamian A, Dworacki G. A case report of lymphoid intestitial pneumonia in common variable immunodeficiency: Oligoclonal expansion of effector lymphocytes with preferential cytomegalovirus-specific immune response and lymphoproliferative disease promotion. Medicine (Baltimore). 2017 Jun;96(23):e7031. [CrossRef]
- Balinisteanu I, Panzaru MC, Caba L, Ungureanu MC, Florea A, Grigore AM, Gorduza EV. Cancer Predisposition Syndromes and Thyroid Cancer: Keys for a Short Two-Way Street. Biomedicines. 2023 Jul 29;11(8):2143. [CrossRef]
- Peng Q, Kong K, Tu Q, Wang Y, Wang X. The role of thyroid hormones in the differential diagnosis of tuberculous and parapneumonic pleural effusions. Am J Med Sci. 2022 Jun;363(6):495-501. [CrossRef]
- Pellegriti G., Mannarino C., Russo M., Terranova R., Marturano I., Vigneri R., Belfiore A. Increased Mortality in Patients With Differentiated Thyroid Cancer Associated With Graves’ Disease J Clin Endocrinol Metab, March 2013, 98(3):1014–1021 . [CrossRef]
- PellegritiG,BelfioreA,GiuffridaD,LupoL,VigneriR.Outcomeof differentiated thyroid cancer in Graves’ patients. J Clin Endocrinol Metab. 1998;83:2805–2809.
- Gabalec F, Srbova L, Nova M, Hovorkova E, Hornychova H, Jakubikova I, Ryska A, Cap J. Impact of Hashimoto's thyroiditis, TSH levels, and anti-thyroid antibody positivity on differentiated thyroid carcinoma incidence. Endokrynol Pol. 2016;67(1):48-53. [CrossRef]
- Anand A, Singh KR, Kushwaha JK, Hussain N, Sonkar AA. Papillary Thyroid Cancer and Hashimoto's Thyroiditis: An Association Less Understood. Indian J Surg Oncol. 2014 Sep;5(3):199-204. [CrossRef]
- Fröhlich E and Wahl R Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases. Front. Immunol.2017; 8:521. [CrossRef]
- Gudmundsson J, et al. Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat. Genet. 2012;44:319–322. [CrossRef]
- Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-85. [CrossRef]
- Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012 Apr;203(4):436-41. [CrossRef]
- Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007;15:415–420.
- Borowczyk M, Sypniewski M, Szyda J, et al. Genetic predisposition to differentiated thyroid cancer in the Polish population. Pol Arch Intern Med. 2024; 134: 16654. [CrossRef]
- Rossi G, Salmanton-García J, Cattaneo C, et al. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings. Int J Infect Dis. 2023;137:98-110. [CrossRef]
- Zdziarski P, Simon K, Majda J. Overuse of high stability antibiotics and its consequences in public and environmental health. Acta Microbiol Pol. 2003;52(1):5-13.
- Zdziarski P. [Importance of the Tumor Boards' decisions for the patientcentered care - case studies in the COVID-19 era]. Pol Merkur Lekarski. 2022 Apr 19;50(296):78-85.
- Bogović Crnčić T, Ilić Tomaš M, Girotto N, Grbac Ivanković S. Risk Factors for Thyroid Cancer: What Do We Know So Far?. Acta Clin Croat. 2020;59(Suppl 1):66-72. [CrossRef]
- Kholová I, Kalfert D, Lintusaari J, Rajakorpi E, Ludvíková M. Follicular Epithelial Dysplasia as Hashimoto Thyroiditis-Related Atypia: a Series of 91 Specimens. Endocr Pathol. 2021 Sep;32(3):368-374. [CrossRef]
- Anand A, Singh KR, Kushwaha JK, Hussain N, Sonkar AA. Papillary Thyroid Cancer and Hashimoto's Thyroiditis: An Association Less Understood. Indian J Surg Oncol. 2014 Sep;5(3):199-204. [CrossRef]
- Zdziarski P, Ricciardi L and Paganelli R Editorial: Case reports in respiratory pharmacology 2022. Front. Pharmacol. 2023; 14:1242273. [CrossRef]
- Casella C, Morandi R, Verrengia A, Galani A, Molfino S, Cuka D, Groppo G, Cappelli C, Portolani N. Thyroid Cancer and Nodules in Graves' Disease: A Single Center Experience. Endocr Metab Immune Disord Drug Targets. 2021;21(11):2028-2034. [CrossRef]
- Kaczka K, Mikosiński S, Fendler W, Celnik A, Pomorski L. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection. Adv Clin Exp Med. 2012 Mar-Apr;21(2):169-78. PMID: 23214280.
- Ali A. A Lump in the Throat: Thyroid Cancer. Medscape Drugs & Diseases. Updated September 13, 2024. Available at: https://reference.medscape.com/slideshow/thyroid-cancer-6006981?ecd=wnl_critimg_241004_mscpref_etid6878122&uac=103670FR&impID=6878122#1 Accessed October 8, 2024.
- Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212. [CrossRef]
- Vargas-Uricoechea, H., Bonelo-Perdomo, A., Sierra-Torres, C.H., Meza-Cabrera, I. (2016). Autoimmune Thyroid Disease (Flajani-Parry-Graves-von Basedow Disease): Etiopathogenesis, Clinical Manifestations and Diagnosis. In: Imam, S., Ahmad, S. (eds) Thyroid Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-25871-3_5.
- Płoski R, Szymański K, Bednarczuk T. The genetic basis of graves' disease. Curr Genomics. 2011 Dec;12(8):542-63. [CrossRef]
- -Skowronek I. IPEX Syndrome: Genetics and Treatment Options. Genes (Basel). 2021;12(3):323. Published 2021 Feb 24. [CrossRef]
- Rezzónico J. N., Rezzónico M., Pusiol E., Pitoia F., and Niepomniszcze H., Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma, Metabolic Syndrome and Related Disorders. (2009) 7, no. 4, 375–380, 2-s2.0-68549090727. [CrossRef]
- Wang J, Li X, Shen B, Wang S, He J and Wang Y (2022) The therapeutic effect of glucocorticoids on type II respiratory failure, heart failure, and massive pericardial effusion caused by hypothyroidism: A case report. Front. Pharmacol. 13:900701. [CrossRef]
- Wawrzynska L, Sakowicz A, Rudzinski P, Langfort R, Kurzyna M. The conversion of thyroxine to triiodothyronine in the lung: comparison of activity of type I iodothyronine 5' deiodinase in lung cancer with peripheral lung tissues. Monaldi Arch Chest Dis. 2003 Apr-Jun;59(2):140-5.
- Jara, L.J., Vera-Lastra, O., Medina, G. (2008). Atrophic Thyroiditis. In: Shoenfeld, Y., Cervera, R., Gershwin, M.E. (eds) Diagnostic Criteria in Autoimmune Diseases. Humana Press. https://doi.org/10.1007/978-1-60327-285-8_42.
- S. Filetti, A. Belfiore, S.M. Amir, G.H. Daniels, O. Ippolito, R. Vigneri, et al. The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancerN Engl J Med, 318 (12) (1988), pp. 753-759.
- Casella C, Morandi R, Verrengia A, Galani A, Molfino S, Cuka D, Groppo G, Cappelli C, Portolani N. Thyroid Cancer and Nodules in Graves' Disease: A Single Center Experience. Endocr Metab Immune Disord Drug Targets. 2021;21(11):2028-2034. [CrossRef]
- Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012 Apr;203(4):436-41. [CrossRef]
- Cheng SP, Hsu YC, Liu CL, Liu TP, Chien MN, Wang TY, Lee JJ. Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma. Ann Surg Oncol. 2014 Dec;21 Suppl 4:S619-26. [CrossRef]
- Huang J, Wang J, Xv J, Wang J, Wang G, Zhao Y. Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study. Clin Exp Med. 2024 Apr 12;24(1):76. [CrossRef]
- Gale RP. Paraneoplastic syndromes. Merck Manual Professional Version, Sep 2024. Accessed September 01, 2024. https://www.merckmanuals.com/professional/hematology-and-oncology/overview-of-cancer/paraneoplastic-syndromes?query=paraneoplastic%20syndromes%20cancer.
- Gale RP. Metastatic Carcinoma of Unknown Primary Origin. Merck Manual Professional Version, Sep 2024. Accessed September 01, 2024. https://www.merckmanuals.com/professional/hematology-and-oncology/overview-of-cancer/metastatic-carcinoma-of-unknown-primary-origin?query=cancer%20unknown%20origin.


| P1 | P2 | P3 | NORM | ||
|---|---|---|---|---|---|
| Gender | F | F | F | ||
| Age | 67 | 71 | 69 | ||
| Thyroid disease | De Quervain’s thyroiditis | Graves disease | Atrophic thyroiditis | ||
| Initial manifestation | Tachycardia, (FT3/4 fluctuation) |
Thyreotoxicosis (exophthalmos) |
Hypertension, oedema, insulin resistance | ||
| BMI | 20→15 | 13.4 | 26.64→22.98 | ||
| Lymphadenopaty | no | no | no | ||
| infection | TBC | TBC | MOT | ||
| Overall survival | 2.5 | 3.5 | live | [year] | |
| Albumin | 3.1 | 2.8 | 4.3 | ||
| Protein | 5.0 | 4.7 | 6 | ||
| Uric acid | 3.2 | 5.0 | 10.0 | ||
| Fasting glucose | 65 | 74 | 153 | 74-106 | [mg/dl] |
| Procalcitonin | 0.08 | 0.06 | 0.09 | [ng/ml] | |
| Calcium (total) | 2.32 | 2.12 | 1.18 | 2.2-2.55 | [mmol/l] |
| Calcium+2 (1.15-1.29) | 0.82 | 1.24 | 0.98 | 1.15-1.29 | [mmol/l] |
|
TSH (during TC diagnosis) |
4,33 | <0.005 | 12.13 | 0.27-4.2 | [μIU/ml] |
| FT4 | 2.2→1.0 | 0.96 | 0.92 | 0.93-1.7 | [ng/dl] |
| FT3 | 5.13→2.0 | 2.43 | 0.74 | 2-4.4 | [pg/ml] |
| Anti-TPO | 1:320 | 1:320 | 47.8* IU/ml | <1:100 | <34IU/ml |
| Anti-TSHR | (-) | >1:1280 | <0.80* IU/ml | <1:100 | <1.50IU/ml |
| Anti-TG | 1:1280 | >1:1280 | 984.0* IU/ml | <1:100 | <115IU/ml |
| Abnormalities in water/electrolyte balance | pleural effusion hypotonia |
Ca++=1.12 mmol/l | Oedema | ||
| BONE | Systemic osteopenia | Calcinosis | osteoporosis with pathological fractures | ||
| Dominating process | Various (autoimmunity→cancer) |
Various (cancer≈mycobacterial) |
mycobacterial | ||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).